Spots Global Cancer Trial Database for A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma

Study Description

Brief Summary: This is a single-arm, non-randomised study including patients with EBER positive nasopharyngeal carcinoma with recurrent or metastatic disease not amenable to curative treatment, who have received at least 1 regimen of platinum containing chemotherapy.

Detailed Description: HYPOTHESIS Given the favourable activity of fluoropyrimidines (5Fluorouracil) which inhibit thymidylate synthase (TS) in nasopharyngeal carcinoma, the investigators hypothesized that TAS-102 may demonstrate efficacy in NPC through targeting TS as well as an additional mechanism of incorporating trifluridine triphosphate into DNA. OBJECTIVES OF TRIAL 1. To determine the clinical efficacy of TAS-102 in recurrent and metastatic NPC 2. To assess the safety and tolerability of TAS-102 in the study population of R/M NPC 3. To study the pharmacokinetics of TAS-102 in the study population of R/M NPC 4. To study potential predictive biomarkers for clinical benefit from TAS-102

Keywords

Eligibility

Minimum Age: 21 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Contact Details

Useful links and downloads for this trial